​

Avalo Therapeutics Ownership | Who Owns Avalo Therapeutics?

OverviewForecastRevenueFinancialsChart

Avalo Therapeutics Ownership Summary

Avalo Therapeutics is owned by 24.20% institutional investors, 1.61% insiders, and 74.19% retail investors. Fmr is the largest institutional shareholder, holding 21.48% of AVTX shares. T. Rowe Price US Small-Cap Core Equity is the top mutual fund, with 2.77% of its assets in Avalo Therapeutics shares.

AVTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockAvalo Therapeutics24.20%1.61%74.19%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.80%11.85%52.35%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr2.88M21.48%$42.99M
T. rowe price investment management2.16M16.13%$32.29M
Caligan partners lp1.64M12.20%$24.41M
Bvf inc/il1.63M12.18%$24.38M
Avoro capital advisors1.41M10.52%$21.05M
Affinity asset advisors1.34M10.00%$20.02M
Nantahala capital management1.24M9.21%$18.44M
Ubs group1.14M8.52%$17.05M
Point72 asset management916.14K6.83%$13.68M
Farallon capital management916.00K6.83%$13.68M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Velan capital investment management lp185.12K1.73%$2.76M
Caligan partners lp1.64M1.62%$24.41M
Pivotal bioventure partners investment advisor295.93K1.58%$4.42M
Ally bridge group (ny)178.10K1.38%$2.26M
Exome asset management159.34K1.23%$2.38M
Affinity asset advisors1.34M1.03%$20.02M
Bvf inc/il1.63M0.78%$24.38M
Nantahala capital management1.24M0.68%$18.44M
Acuta capital partners60.81K0.64%$907.86K
Boxer capital management300.00K0.59%$4.48M

Top Buyers

HolderShares% AssetsChange
Fmr2.88M0.00%2.66M
T. rowe price investment management2.16M0.02%2.16M
Avoro capital advisors1.41M0.21%1.41M
Farallon capital management916.00K0.08%916.00K
Rtw investments, lp856.96K0.13%856.96K

Top Sellers

HolderShares% AssetsChange
Orbimed advisors475.17K0.14%-712.13K
Silverarc capital management---524.44K
Marshall wace, llp129.14K0.00%-378.41K
Patient square capital lp---311.97K
Citadel advisors193.74K0.00%-225.76K

New Positions

HolderShares% AssetsChangeValue
T. rowe price investment management2.16M0.02%2.16M$32.29M
Avoro capital advisors1.41M0.21%1.41M$21.05M
Farallon capital management916.00K0.08%916.00K$13.68M
Rtw investments, lp856.96K0.13%856.96K$12.79M
Kennedy capital management387.98K0.12%387.98K$5.79M

Sold Out

HolderChange
Raymond james financial-1.00
Group one trading-1.00
Sbi securities-23.00
Simplex trading-748.00
Citigroup-1.14K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202622-76.34%3,244,082-83.69%240.12%14-77.42%2-84.62%
Dec 31, 202541-41.43%8,217,986-46.35%580.29%30-36.17%4-50.00%
Sep 30, 20256997.14%14,834,68589.14%1362.61%47261.54%8-33.33%
Jun 30, 2025356.06%7,843,040-4.99%721.18%13-13.33%12200.00%
Mar 31, 202533-8,255,0579.62%781.52%15-11.76%433.33%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
T. Rowe Price US Small-Cap Core Equity678.82K2.77%678.82K
T. Rowe Price Small-Cap Stock678.82K2.77%678.82K
Vanguard Total Stock Mkt Idx Inv537.79K2.01%-
FIAM Small Cap Core CIT Cl B522.10K1.95%522.10K
T. Rowe Price Small-Cap Value379.09K1.55%379.09K
T. Rowe Price Instl Small-Cap Stock348.39K1.42%348.39K
Fidelity Advisor Biotechnology I358.30K1.34%-
T. Rowe Price U.S. SC Core Eq Tr-D322.06K1.31%322.06K
Kennedy Micro Cap247.47K1.01%247.47K
T. Rowe Price U.S. SC Value Eq Tr-D247.44K1.01%247.44K

Recent Insider Transactions

DateNameRoleActivityValue
May 28, 2026Doyle Mittie Chief Medical OfficerSell$10.86K
May 15, 2026Doyle Mittie Chief Medical OfficerSell$56.28K
May 07, 2026Sullivan Christopher Ryan Chief Financial OfficerSell$448.82K
May 06, 2026VARKI PAUL Chief Legal OfficerSell$706.84K
May 06, 2026VARKI PAUL Chief Legal OfficerSell$484.54K

Insider Transactions Trends

DateBuySell
2026 Q2-28
2026 Q1-1
2025 Q4-2
2025 Q3--
2025 Q2--

AVTX Ownership FAQ

Who Owns Avalo Therapeutics?

Avalo Therapeutics shareholders are primarily institutional investors at 24.20%, followed by 1.61% insiders and 74.19% retail investors. The average institutional ownership in Avalo Therapeutics's industry, Biotech Stocks , is 35.80%, which Avalo Therapeutics falls below.

Who owns the most shares of Avalo Therapeutics?

Avalo Therapeutics’s largest shareholders are Fmr (2.88M shares, 21.48%), T. rowe price investment management (2.16M shares, 16.13%), and Caligan partners lp (1.64M shares, 12.20%). Together, they hold 49.81% of Avalo Therapeutics’s total shares outstanding.

Does Blackrock own Avalo Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Avalo Therapeutics.

Who is Avalo Therapeutics’s biggest shareholder by percentage of total assets invested?

Velan capital investment management lp is Avalo Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.73% of its assets in 185.12K Avalo Therapeutics shares, valued at 2.76M$.

Who is the top mutual fund holder of Avalo Therapeutics shares?

T. Rowe Price US Small-Cap Core Equity is the top mutual fund holder of Avalo Therapeutics shares, with 2.77% of its total shares outstanding invested in 678.82K Avalo Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools